share_log

双鹭药业(002038.SZ):长效立生素技术审评已完成,正在进行文件制作审核批件

Shuanglu Pharmaceutical (002038.SZ): The technical review of long-term biotin has been completed, and the document preparation review and approval is in progress

Gelonghui Finance ·  Sep 15, 2023 04:15

Gelonghui September 15?Some investors asked Shuanglu Pharmaceutical (002038.SZ) on the investor interactive platform, "is it normal to review the listing of long-acting probiotics so far (2023-9-12)?" At present, are you waiting for CDE approval or CDE for your submission? " The company replied that the technical review of its long-acting probiotics has been completed and is in the process of document production and approval.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment